Live Breaking News & Updates on A Oliver Sartor

Stay updated with breaking news from A oliver sartor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Radioligand Therapy Continues to Show Promise for Metastatic CRPC

Median OS of 15.5 months, PFS of 7.9 months with Ac-225-PSMA in heavily treated patients ....

South Africa , Mayo Clinic In Rochester , United States , A Oliver Sartor , Mikem Sathekge , Charles Bankhead , University Of Pretoria , Mayo Clinic , Medpage Today ,

ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer

ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United States , Oliver Sartor , A Oliver Sartor , Zachary Klaassen , Georgia Cancer Center , Disease Group Leader Gu Cancers , European Society Of Medical Oncology , Disease Group Leader , Radiopharmaceutical Trials , Mayo Clinic , Urologic Oncologist , Associate Professor , Medical Oncology , Annual Meeting ,

Lutetium Lu 177 Vipivotide Tetraxetan Improves rPFS in Taxane-Naïve mCRPC After Prior ARPI

Treatment with lutetium Lu 177 vipivotide tetraxetran improved radiographic progression-free survival compared with abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer who were taxane naïve and experienced disease progression on a prior second-generation androgen receptor pathway inhibitor. ....

Mayo Clinic In Rochester , United States , A Oliver Sartor , Mayo Clinic , Lutetium Lu 177 Vipivotide Tetraxetran ,

Pluvicto Improves Survival Without Progression in Certain Patients With Prostate Cancer

Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto. ....

Mayo Clinic In Rochester , United States , A Oliver Sartor , Zytiga Xtandi , European Society For Medical Oncology Annual Congress , Medical Oncology Annual Congress , Mayo Clinic , Prostate Cancer , Esmo 2023 ,

ASCO GU 2022: Quantitative Assessment of PSMA Imaging Before and After 177Lu-PSMA-617 Treatment in a Phase I/II Trial

ASCO GU 2022: Quantitative Assessment of PSMA Imaging Before and After 177Lu-PSMA-617 Treatment in a Phase I/II Trial
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Charlene Thomas , Mahelia Bissassar , Dunya Imad , Muhammad Obaid Naiz , Shankar Vallabhajosula , A Oliver Sartor , Michael Sun , Escarleth Fernandez , Jones Nauseef , Jonest Nauseef , Zachary Klaassen , Scottt Tagawa , Jamie Patel , Joseph Osborne , Sharon Singh , Davidm Nanus , Coran Sternberg , Juana Martinez Zuloaga , Presbyterian Hospital Weill Cornell Medical Center , American Society Of Clinical Oncology , Georgia Cancer Center , Augusta University Medical College Of Georgia , New York Presbyterian , Weill Cornell Medical Center ,